Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Protein Kinase Inhibitors. Found 38 abstracts

no pagination
Webster MR, Fane ME, Alicea GM, Basu S, Kossenkov AV, Marino GE, Douglass SM, Kaur A, Ecker BL, Gnanapradeepan K, Ndoye A, Kugel C, Valiga A, Palmer J, Liu Q, Xu X, Morris J, Yin X, Wu H, Xu W, Zheng C, Karakousis GC, Amaravadi RK, Mitchell TC, Almeida FV, Xiao M, Rebecca VW, Wang YJ, Schuchter LM, Herlyn M, Murphy ME, Weeraratna AT. Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. Molecular cell. 2020 Feb 06;77(3):633-644e5.
Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM. Role of Checkpoint Inhibition in Localized Bladder Cancer. European urology oncology. 2018 Aug;1(3):190-8.
von Mehren M, Joensuu H. Gastrointestinal Stromal Tumors. J Clin Oncol. 2018 Jan 10;36(2):136-43.   PMCID: PMC6553810
Hou P, Wu C, Wang Y, Qi R, Bhavanasi D, Zuo Z, Dos Santos C, Chen S, Chen Y, Zheng H, Wang H, Perl A, Guo D, Huang J. A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220. Cancer Res. 2017 Aug 15;77(16):4402-13.   PMCID: PMC5559306
Lu H, Liu S, Zhang G, Bin W, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. 2017 Oct 05;550(7674):133-6.   PMCID: PMC5891348
Prudnikova TY, Chernoff J. The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin. Small GTPases. 2017 Oct 02;8(4):193-8.   PMCID: PMC5680705
Ursu O, Gosline SJ, Beeharry N, Fink L, Bhattacharjee V, Huang SC, Zhou Y, Yen T, Fraenkel E. Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens. PLoS One. 2017 Oct;12(10):e0185650.   PMCID: PMC5638242
Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Muschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood. 2016 Apr 28;127(17):2131-43.   PMCID: PMC4850868
Haldane A, Flynn WF, He P, Vijayan RS, Levy RM. Structural propensities of kinase family proteins from a Potts model of residue co-variation. Protein science : a publication of the Protein Society. 2016 Aug;25(8):1378-84.   PMCID: PMC4972195
Ji W, Arnst C, Tipton AR, Bekier ME, Taylor WR, Yen TJ, Liu ST. OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases. PLoS One. 2016 Jan;11(4):e0153518.   PMCID: PMC4833387
Ji W, Arnst C, Tipton AR, Bekier ME, Taylor WR, Yen TJ, Liu ST. OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases. PLoS One. 2016 Jan;11(4):e0153518.   PMCID: PMC4833387
Hochster HS, Uboha N, Messersmith W, Gold PJ, O Neil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L, Lenz HJ. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015 Jan;75(1):17-23.
Najjar M, Suebsuwong C, Ray S, Thapa R, Maki J, Nogusa S, Shah S, Saleh D, Gough P, Bertin J, Yuan J, Balachandran S, Cuny G, Degterev A. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. Cell Reports. 2015 Mar 24;10(11):1850-60.   PMCID: 4494889
Vijayan RS, He P, Modi V, Duong-Ly KC, Ma HC, Peterson JR, Dunbrack RL, Levy RM. Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors. Journal of medicinal chemistry. 2015 Jan;58(1):466-79.   PMCID: 4326797
Zhang I, Zaorsky NG, Palmer JD, Mehra R, Lu B. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol. 2015 Oct;16(13):e510-21.
Ali SM, Alpaugh RK, Buell JK, Stephens PJ, Yu JQ, Wu H, Hiemstra CN, Miller VA, Lipson D, Palmer GA, Ross JS, Cristofanilli M. Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. Clin Breast Cancer. 2014 Feb;14(1):e14-6.
Plimack ER, Tan T, Wong YN, von Mehren MM, Malizzia L, Roethke SK, Litwin S, Li T, Hudes GR, Haas NB. A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma. The oncologist. 2014 Apr;19(4):354-5.   PMCID: Pmc3983829
Vijayvergia N, Mehra R. Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2014 Sep;74(3):437-46.
Anastassiadis T, Duong-Ly KC, Deacon SW, Lafontant A, Ma H, Devarajan K, Dunbrack RL, Wu J, Peterson JR. A highly selective dual insulin receptor (IR)/insulin-like growth factor 1 receptor (IGF-1R) inhibitor derived from an extracellular signal-regulated kinase (ERK) inhibitor. The Journal of biological chemistry. 2013 Sep 27;288(39):28068-77.   PMCID: PMC3784719
Cohen RB, Aamdal S, Nyakas M, Cavallin M, Green D, Learoyd M, Smith I, Kurzrock R. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer. 2013 May;49(7):1521-9.   PMCID: *
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Protein Kinase Inhibitors

Protein Kinase Inhibitors antagonists & inhibitors genetics drug therapy pharmacology metabolism drug effects therapeutic use pathology Mutation Neoplasm Drug Resistance Signal Transduction Tumor Cell Line Female physiology chemistry Antineoplastic Agents adverse effects Apoptosis Mice Male Pyridazines Middle Aged immunology enzymology Protein Binding Drug Dose-Response Relationship Molecular Targeted Therapy Drug Administration Schedule Antibodies p21-Activated Kinases MAP Kinase Signaling System Antineoplastic Combined Chemotherapy Protocols Kinetochores pharmacokinetics HeLa Cells Protein Databases Melanoma Lung Neoplasms Imidazoles Protein Conformation Pyrazoles Treatment Outcome Amino Acid Sequence MAP Kinase Kinase Kinases Phosphorylation Non-Small-Cell Lung Carcinoma Molecular Models Proto-Oncogene Proteins B-raf Mitosis Protein-Serine-Threonine Kinases Naphthyridines Tumor Microenvironment Neoplasm Proteins Oncogene Proteins v-abl Aurora Kinase B MCF-7 Cells Amino Acid Motifs analogs & derivatives Adult TOR Serine-Threonine Kinases Cell Proliferation M Phase Cell Cycle Checkpoints Receptor Protein-Tyrosine Kinases secondary Centromere SCID Mice Inflammatory breast cancer Proto-Oncogene Proteins Next-generation sequencing antagonists & Trastuzumab Acetophenones slow-cycling phenotype ovarian cancer Mitogen-Activated Protein Kinase 14 Non-muscle-invasive Neoplastic Stem Cells classification Proto-Oncogene Proteins c-abl Platelet-Derived Growth Factor alpha Receptor Human Chromosomes-Pair 11 Experimental Leukemia Enzyme Activation Molecular Docking Simulation Wnt-5a Protein Acne Vulgaris protein kinase Potts model Fatigue oncogene Protein Kinase C epidemiology Survival Analysis Bryostatins Camptothecin Biocatalysis surgery conformational preference Area Under Curve Phenylurea Compounds Transitional Cell Carcinoma pd-1 JNK Mitogen-Activated Protein Kinases Cell Cycle Checkpoints IGF Type 1 Receptor DNA Repair Local Neoplasm Recurrence Small Molecule Libraries Secondary Protein Structure mortality Insulin Receptor therapy resistance CTLA-4 Antigen X-Ray Crystallography pd-l1 use chromosomal amplification Kinetics Oxidative Stress Pancreatic Neoplasms B7-H1 Antigen Tumor Biomarkers Piperidines MAP Kinase Kinase 2 beta Catenin Metabolic Clearance Rate Sarcoma Young Adult Adenosine Triphosphate Biological Models ras Proteins etiology Mitogen-Activated Protein Kinases ctla-4 aged microenvironment Preclinical Drug Evaluation Jurkat Cells therapeutic adverse Dermatitis Myeloid Leukemia-Acute Brain Neoplasms Epidermal Growth Factor Receptor methods Algorithms Allosteric Regulation Thermodynamics HEK293 Cells Her2
Last updated on Friday, August 07, 2020